{"entity":{"id":"sgr-2921","kind":"drug","name":"SGR-2921","aka":[],"tldr":"SGR-2921 is a small molecule from Schrödinger that reached phase 1 for relapsed or refractory acute myeloid leukaemia and myelodysplastic syndrome; development has stopped.","summary":"SGR-2921 is a small molecule (oral) from Schrödinger. A CDC7 inhibitor. Its furthest stage is phase 1, for relapsed or refractory acute myeloid leukaemia and myelodysplastic syndrome. ClinicalTrials.gov registers it in one study linked below. Discontinued in August 2025 per Schrödinger's 10-Q for the quarter to 30 June 2026; the phase 1 trial NCT05961839 is TERMINATED on the registry. Whether it works in people has not been established unless a trial below reports it.","status":"phase-1","asOf":"2026-11-03","links":[{"label":"Schrödinger: sec.gov","url":"https://www.sec.gov/Archives/edgar/data/1490978/000149097826000068/sdgr-20260630.htm"},{"label":"Schrödinger: sec.gov","url":"https://www.sec.gov/Archives/edgar/data/1490978/000149097825000099/sdgr-20250630xexx991.htm"},{"label":"ClinicalTrials.gov: trials of SGR-2921","url":"https://clinicaltrials.gov/search?intr=SGR-2921"}],"tags":["pipeline","ctgov-ingest","discontinued"],"related":[],"cancers":["aml","mds"],"sections":[],"technologies":[],"targets":["cdc7"],"drugs":[],"companies":["schrodinger"],"institutions":[],"pathways":[],"terms":[],"trials":["nct05961839"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo gap audit, class 5 (company pipeline pages and ClinicalTrials.gov v2)","editedOn":"2026-11-03"},"code":"SGR-2921","modality":"Small molecule (oral)","mechanism":"A CDC7 inhibitor.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/sgr-2921/","neighbours":{"cancer":[{"id":"aml","kind":"cancer","name":"Acute myeloid leukaemia","route":"/cancers/aml/"},{"id":"mds","kind":"cancer","name":"Myelodysplastic syndromes / neoplasms (MDS)","route":"/cancers/mds/"}],"target":[{"id":"cdc7","kind":"target","name":"CDC7","route":"/targets/cdc7/"}],"company":[{"id":"schrodinger","kind":"company","name":"Schrödinger","route":"/companies/schrodinger/"}],"trial":[{"id":"nct05961839","kind":"trial","name":"Study of SGR-2921 in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome","route":"/trials/nct05961839/"}]}}